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Abstract
Background: Childhood cancer survivors are at risk of subsequent primary soft-tissue sarcomas (STS), but the risks of specific STS
histological subtypes are unknown. We quantified the risk of STS histological subtypes after specific types of childhood cancer.
Methods: We pooled data from 13 European cohorts, yielding a cohort of 69 460 five-year survivors of childhood cancer.
Standardized incidence ratios (SIRs) and absolute excess risks (AERs) were calculated.
Results: Overall, 301 STS developed compared with 19 expected (SIR ¼ 15.7, 95% confidence interval [CI] ¼ 14.0 to 17.6). The
highest standardized incidence ratios were for malignant peripheral nerve sheath tumors (MPNST; SIR ¼ 40.6, 95% CI¼29.6 to
54.3), leiomyosarcomas (SIR ¼ 29.9, 95% CI¼23.7 to 37.2), and fibromatous neoplasms (SIR ¼ 12.3, 95% CI¼9.3 to 16.0). SIRs for
MPNST were highest following central nervous system tumors (SIR ¼ 80.5, 95% CI¼48.4 to 125.7), Hodgkin lymphoma (SIR ¼
81.3, 95% CI¼35.1 to 160.1), and Wilms tumor (SIR ¼ 76.0, 95% CI¼27.9 to 165.4). Standardized incidence ratios for
leiomyosarcoma were highest following retinoblastoma (SIR ¼ 342.9, 95% CI¼245.0 to 466.9) and Wilms tumor (SIR ¼ 74.2,
95% CI¼37.1 to 132.8). AERs for all STS subtypes were generally low at all years from diagnosis (AER < 1 per 10 000 person-
years), except for leiomyosarcoma following retinoblastoma, for which the AER reached 52.7 (95% CI¼20.0 to 85.5) per 10 000
person-years among patients who had survived at least 45 years from diagnosis of retinoblastoma.
Conclusions: For the first time, we provide risk estimates of specific STS subtypes following childhood cancers and give evidence
that risks of MPNSTs, leiomyosarcomas, and fibromatous neoplasms are particularly increased. While the multiplicative excess
risks relative to the general population are substantial, the absolute excess risk of developing any STS subtype is low, except for
leiomyosarcoma after retinoblastoma. These results are likely to be informative for both survivors and health care providers.
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Within Europe, 79% of children diagnosed with cancer now sur-
vive at least five years (1). This high survival rate has resulted in
a large population of long-term survivors of childhood cancer
(2). Childhood cancer survivors are at risk of long-term adverse
health outcomes, with one of the most serious being the devel-
opment of subsequent primary neoplasms (SPNs)—with the
overall risk being three- to sixfold that expected from the gen-
eral population (3–8).
Previous studies have shown that the risk of developing any
subsequent primary soft-tissue sarcoma (STS) is substantially
elevated following childhood cancer, particularly in survivors of
heritable retinoblastoma and Wilms tumor (3–6,9–18). However,
because development of an STS is rare, previous reports were
based on small observed numbers, and, to our knowledge, no
previous study has reported risk estimates for specific
histological subtypes of STS after all and specific types of child-
hood cancer, except after hereditary retinoblastoma (15,16).
Supplementary Table 1 (available online) presents the number
of survivors and STS SPNs included in these previous studies.
Because of the increased awareness of treatment-related ad-
verse health outcomes among childhood cancer survivors,
recent treatments for childhood cancers with a favorable prog-
nosis have moved toward lowering therapeutic exposures. So
far, the potential impact of such lower therapeutic exposure on
the risk of STS SPNs has not been investigated.
We investigated the risks of STS within a large-scale pan-
European cohort of 69 460 five-year survivors of childhood can-
cer. The current study provides more than threefold the number
of STS provided by the largest study on STS SPN published to
date, which is not included in the present study (9). The aim of
this study was to provide risk estimates for all and specific his-
tological subtypes of STS after all and specific types of child-
hood cancer.
Methods
The PanCare Childhood and Adolescent Cancer Survivor
Care and Follow-Up Studies
The PanCare Childhood and Adolescent Cancer Survivor Care
and Follow-Up Studies (PanCareSurFup) consortium pools data
from across Europe to form the largest collaborative study to
date to investigate adverse health outcomes in long-term survi-
vors of childhood and adolescent cancer (referred to as child-
hood cancer henceforth). The PanCareSurFup cohort comprises
data from 13 European cohorts, within 12 countries, of child-
hood cancer survivors, with contributions from both
population-based cancer registries and major treatment cen-
ters. Ethical approval was obtained separately for each cohort
from the appropriate bodies within each specific country.
Written consent from participants or appropriate legal permis-
sion to process individual patient data without individual con-
sent was obtained within each specific country as well.
Cohort Ascertainment
Childhood cancers were coded according to the first, second, or
third revision of the International Classification of Disease for
Oncology (ICD-O). To enable childhood cancers to be grouped
according to the International Classification of Childhood
Cancers (ICCC) (19), morphology and topography codes were
converted into ICD-O-3 using the IARC/IACR Cancer Registry
Tools software (20). Cancers in Slovenia prior to 1983 were
coded by topography only (ICD7) and therefore could not be
classified according to the ICCC; these individuals were grouped
into a separate “not classifiable” childhood cancer group. All
remaining cancers that were not classifiable to the ICCC were
excluded. Individuals with Langerhans cell histiocytosis, myelo-
dysplastic syndromes, chronic myeloproliferative and lympho-
proliferative disorders, or immunoproliferative diseases were
excluded as these conditions were not ascertained satisfactorily
by all countries (Supplementary Figure 1, available online). In
total, the cohort consists of 69 460 five-year survivors of cancer
diagnosed before age 20 years between 1940 and 2008
(Supplementary Tables 2 and 3, available online).
Subsequent Primary Neoplasm Ascertainment
SPNs were ascertained through several different methods, and
the primary method of validation was through pathology
reports or, in their absence, other means of clinical diagnosis
(see Supplementary Table 2, available online). To be included as
an SPN, tumors had to have a different histological classifica-
tion than that of the childhood cancer (first primary neoplasm
[FPN]) and have a malignant behavior code (see Supplementary
Figure 2, available online). The majority (70%) of affected indi-
viduals in the cohort were age 15 to 39 years at diagnosis of an
STS; therefore, STS SPNs were classified using the adolescent
and young adult (AYA) cancer classification scheme (21).
General Population STS Rates for the Derivation of
Expected Numbers
To compare the observed number of STS SPNs with the
expected numbers from the general population, general popula-
tion STS incidence rates formatted according to the AYA classi-
fication (by ICD-O morphology) were required. Incidence rates
by ICD-O morphology were available for the United Kingdom
(years 1971–2006: England and Wales only) (22) and Finland
(years 1953–2011) (23). Finnish rates were used for all Nordic
countries (Finland, Sweden, Denmark, Iceland, and Norway)
because of close geographical proximity and similar health care
systems. UK rates were used for all other countries (UK, France,
Hungary, Italy, Netherlands, Slovenia, and Switzerland). When
the range of calendar-years for the general population cancer
rates did not extend to the ascertainment period of STS, rates
from the closest available year were used.
Genetic Predisposition Syndromes and Radiotherapy
Exposure
Information on genetic predispositions was obtained from med-
ical notes for survivors who developed an STS. In addition, in-
formation on the exact site of the STS and previous
radiotherapy fields was obtained to establish whether the STS
was located in previously irradiated sites.
Statistical Analysis
Follow-up began at five-year survival from childhood cancer
and ended at the first occurrence of death, loss to follow-up, or
cohort exit date. The number lost to follow-up did not exceed
6% (specific numbers are given in Supplementary Table 2, avail-
able online). Analyses involving observed and expected num-
bers allowed multiple STS per individual. Standardized
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incidence ratios (SIRs) were calculated as the observed divided
by the expected number of STS. The expected number of STS
was calculated by accumulating person-years in the cohort by
sex, single calendar-year and five-year age strata and multiply-
ing by the corresponding general population STS incidence
rates. Absolute excess risks (AERs) were calculated as the ob-
served minus the expected number of STS, divided by person-
years at risk and multiplied by 10 000. The absolute excess risk
can be interpreted as the number of excess STS observed be-
yond that expected per 10 000 persons per year. We often report
the absolute excess risk without specifying the underlying
person-years at risk because this is always per 10 000 persons
per year. Standardized incidence ratios and absolute excess
risks were stratified by sex, country, childhood cancer type, age
at and decade of childhood cancer diagnosis, attained age, and
years from childhood cancer diagnosis for STS subtypes where
numbers were sufficient (n > 40). The simultaneous effect of
these potential explanatory factors was analyzed using multi-
variable Poisson regression with a user-defined link function to
calculate relative risks (RRs) and relative excess risks (RER) (24).
Relative risks can be interpreted as the ratio of standardized in-
cidence ratios adjusted for other explanatory factors. Relative
excess risks can be interpreted as the ratio of absolute excess
risks adjusted for other explanatory factors.
Cumulative incidence for the first occurrence of a subse-
quent STS was computed by years since five-year survival by
means of the stcompet command in Stata (25). Death due to any
cause prior to developing a subsequent STS was treated as a
competing event. Expected cumulative incidence was calcu-
lated using the Ederer II method (26,27). All statistical analyses
were conducted in Stata statistical software, version 14.1.
Likelihood ratio tests comparing the deviance of a model con-
taining the variable of interest (eg, age at diagnosis), which was
coded such that it had the median value of the variable at each
level, with the deviance of a model without the variable of inter-
est were used to calculate P values for linear trend and hetero-
geneity. A two-sided P value of less than .05 was considered
statistically significant.
Results
Cohort Characteristics
Overall, individuals contributed 1 126 424 person-years and a
median follow-up of 14.5 years from five-year survival (range ¼
0–62 years). A total of 301 STS were observed among 299 of the
69 460 five-year survivors of childhood cancer (Table 1). The me-
dian time from diagnosis to occurrence of an STS was 19 years
(data not shown). The most commonly observed STS were leio-
myosarcoma (n¼ 80, 26.6%), fibromatous neoplasms (n¼ 55,
18.3%), and MPNSTs (n¼ 45, 15.0%) (Table 1). The median times
from diagnosis to occurrence of a leiomyosarcoma, fibromatous
neoplasm, and MPNST were 33, 16, and 17 years, respectively
(data not shown).
Overall Risk of STS
Overall, survivors had a 15.7-fold (95% confidence interval [CI] ¼
14.0 to 17.6) risk of developing an STS compared with that
expected from the general population, corresponding to an ab-
solute excess risk of 2.5 (95% CI¼ 2.2 to 2.8) (Table 2). Survivors
of each specific type of childhood cancer were at a statistically
significantly increased multiplicative (SIR) and absolute (AER)
excess risk of developing an STS, particularly retinoblastoma
survivors (SIR ¼ 72.8, 95% CI¼ 56.1 to 93.0; AER ¼ 10.5, 95%
CI¼ 7.9 to 13.1). The multivariable analysis revealed that there
was no statistically significant relationship between age at diag-
nosis or decade of diagnosis and the excess risk of STS in either
multiplicative or absolute terms. The relative risk declined by
50% among survivors older than age 40 years compared with
survivors age 0 to 19 years (RR¼ 0.5, 95% CI¼ 0.3 to 0.8, Ptrend ¼
.002); in contrast, the relative excess risk increased 2.9-fold (95%
CI¼ 1.8 to 4.5, Ptrend < .001). The relative risk declined by 50%
among patients who survived at least 45 years since their child-
hood cancer compared with patients who survived five to 14
years (RR¼ 0.5, 95% CI¼ 0.2 to 0.9, Ptrend ¼ .001); in contrast, the
relative excess risk increased 3.7-fold (95% CI¼ 1.9 to 7.2, Ptrend
< .001). Beyond 45 years from diagnosis, the absolute excess
risk was 9.1 (95% CI¼ 3.6 to 14.6). The cumulative incidence of
developing an STS was 1.4% (95% CI¼ 1.1 to 1.6) at 45 years from
diagnosis, whereas 0.1% was expected (Figure 1A).
Risk of Leiomyosarcoma
The standardized incidence ratio of developing a leiomyosar-
coma was 30-fold (95% CI¼ 23.7 to 37.2) among survivors of
childhood cancer compared with the general population, corre-
sponding to an absolute excess risk of 0.7 (95% CI¼ 0.5 to 0.8)
(Table 3). Standardized incidence ratios were highest among
retinoblastoma survivors (SIR ¼ 342.9, 95% CI¼ 245.0 to 466.9)
and Wilms tumor survivors (SIR ¼ 74.2, 95% CI¼ 37.1 to 132.8).
Ninety point nine percent of leiomyosarcomas observed after
Wilms tumor developed within irradiated tissue
(Supplementary Table 4, available online). Standardized inci-
dence ratios were particularly high among survivors diagnosed
Table 1. SIRs and AERs of developing a subsequent primary STS in
69 460 five-year survivors of childhood cancer in the European
PanCareSurFup SPN cohort, by histological type
STS diagnosis O/E SIR (95% CI) AER (95% CI)
All STS 301*/19.2 15.7 (14.0 to 17.6) 2.5 (2.2 to 2.8)
Malignant peripheral
nerve sheath
tumor
45/1.1 40.6 (29.6 to 54.3) 0.4 (0.3 to 0.5)
Leiomyosarcoma 80/2.7 29.9 (23.7 to 37.2) 0.7 (0.5 to 0.8)
Fibromatous
neoplasms
55/4.5 12.3 (9.3 to 16.0) 0.4 (0.3 to 0.6)
Malignant fibrous
histiocytoma
25/0.9 28.3 (18.3 to 41.7) 0.2 (0.1 to 0.3)
Fibrosarcoma 27/1.1 25.1 (16.5 to 36.5) 0.2 (0.1 to 0.3)
Dermatofibroma 3/2.5 1.2 (0.2 to 3.5) 0.0 (–0.0 to 0.0)
Rhabdomyosarcoma 22/1.6 13.4 (8.4 to 20.4) 0.2 (0.1 to 0.3)
Liposarcoma 19/1.8 10.5 (6.3 to 16.4) 0.2 (0.1 to 0.2)
Synovial sarcoma 9/1.3 6.8 (3.1 to 12.9) 0.1 (0.0 to 0.1)
Other specified
sarcoma
4/0.6 6.3 (1.7 to 16.2) 0.0 (–0.0 to 0.1)
Blood vessel tumor 12/2.5 4.8 (2.5 to 8.3) 0.1 (0.0 to 0.1)
Clear cell sarcoma 0/0.1 — —
Alveolar soft part
sarcoma
0/0.1 — —
Unspecified sarcoma 55/2.6 20.9 (15.8 to 27.3) 0.5 (0.3 to 0.6)
*Among 299 individuals. One individual had unspecified sarcoma and fibrosar-
coma; one individual had two separate rhabdomyosarcomas. — ¼ results not re-
liable because of small (or zero) number of STS events; AER ¼ absolute excess
risk per 10 000 person-years; CI ¼ confidence interval; E ¼ expected number of
STS; O ¼ observed number of STS; SIR ¼ standardized incidence ratio.
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Table 2. Risk of developing a subsequent primary STS among 69 460 five-year survivors of childhood cancer, by potential explanatory factors
Factor level O/E SIR (95% CI)* RR (95% CI)† AER (95% CI)* RER (95% CI)†
Overall sex
All combined 301/19.2 15.7 (14.0 to 17.6) 2.5 (2.2 to 2.8)
Male 161/10.5 15.4 (13.1 to 17.9) Ref 2.5 (2.1 to 2.9) Ref
Female 140/8.7 16.1 (13.6 to 19.0) 1.2 (0.9 to 1.5) 2.5 (2.1 to 2.9) 1.0 (0.8 to 1.3)
Pheterogeneity† .65 .23 .99 .92
Country
France 48/1.5 32.2 (23.8 to 42.7) Ref 5.6 (4.0 to 7.2) Ref
Hungary 6/0.6 9.6 (3.5 to 20.9) 0.3 (0.1 to 0.8) 1.1 (0.1 to 2.0) 0.3 (0.1 to 0.8)
Italy (PB) 12/1.0 11.8 (6.1 to 20.5) 0.4 (0.2 to 0.8) 1.6 (0.6 to 2.5) 0.4 (0.2 to 0.8)
Italy (HB) 1/0.3 3.0 (0.1 to 16.6) 0.1 (0.0 to 0.9) 0.3 (–0.6 to 1.1) 0.1 (0.0 to 1.1)
Netherlands 32/1.5 20.8 (14.2 to 29.4) 0.8 (0.5 to 1.3) 2.9 (1.9 to 4.0) 0.8 (0.5 to 1.3)
Denmark 18/1.7 10.3 (6.1 to 16.3) 0.4 (0.2 to 0.7) 2.1 (1.0 to 3.1) 0.4 (0.2 to 0.7)
Sweden 25/2.2 11.4 (7.4 to 16.8) 0.4 (0.3 to 0.7) 2.0 (1.1 to 2.8) 0.4 (0.3 to 0.8)
Norway 9/1.0 9.0 (4.1 to 17.2) 0.3 (0.2 to 0.7) 1.5 (0.4 to 2.6) 0.4 (0.2 to 0.8)
Finland 27/2.3 12.0 (7.9 to 17.4) 0.5 (0.3 to 0.8) 2.4 (1.4 to 3.3) 0.5 (0.3 to 0.8)
Iceland 2/0.1 30.6 (3.7 to 110.7) 1.2 (0.3 to 5.1) 5.6 (–2.4 to 13.6) 1.3 (0.3 to 5.9)
Slovenia 5/0.5 10.9 (3.6 to 25.5) 0.7 (0.2 to 2.0) 1.8 (0.1 to 3.6) 0.7 (0.2 to 2.2)
Switzerland 9/0.6 14.5 (6.6 to 27.5) 0.5 (0.2 to 1.1) 1.8 (0.5 to 3.1) 0.5 (0.2 to 1.1)
UK 107/5.8 18.4 (15.1 to 22.3) 0.5 (0.4 to 0.8) 2.7 (2.2 to 3.3) 0.5 (0.4 to 0.8)
Pheterogeneity <.001 <.001 <.001 .003
Age at diagnosis, y
0–4 142/5.9 24.2 (20.3 to 28.5) Ref 2.9 (2.4 to 3.4) Ref
5–9 50/4.0 12.4 (9.2 to 16.3) 0.9 (0.6 to 1.3) 1.8 (1.3 to 2.3) 0.9 (0.6 to 1.3)
10–14 73/5.2 14.1 (11.0 to 17.7) 1.1 (0.7 to 1.6) 2.7 (2.0 to 3.4) 1.1 (0.7 to 1.7)
15–19 36/4.1 8.9 (6.2 to 12.3) 0.9 (0.5 to 1.5) 2.1 (1.3 to 2.8) 0.8 (0.5 to 1.5)
Ptrend <.001 .951 .150 .937
Type of first childhood cancer
Leukemia 19/2.8 6.8 (4.1 to 10.6) Ref 0.7 (0.3 to 1.1) Ref
Hodgkin lymphoma 33/1.7 19.0 (13.1 to 26.7) 3.2 (1.8 to 5.8) 3.6 (2.3 to 4.9) 3.5 (1.8 to 6.8)
Non-Hodgkin lymphoma 8/1.0 8.1 (3.5 to 16.0) 1.3 (0.6 to 3.0) 1.3 (0.3 to 2.3) 1.3 (0.5 to 3.4)
Central nervous system 42/4.0 10.4 (7.5 to 14.0) 1.7 (1.0 to 3.0) 1.7 (1.1 to 2.2) 1.8 (1.0 to 3.4)
Neuroblastoma 17/0.7 24.5 (14.3 to 39.2) 3.0 (1.5 to 5.8) 3.0 (1.5 to 4.4) 3.2 (1.5 to 6.7)
Retinoblastoma 64/0.9 72.8 (56.1 to 93.0) 10.9 (6.3 to 19.0) 10.5 (7.9 to 13.1) 12.2 (6.6 to 22.7)
Wilms tumor 34/1.3 25.5 (17.6 to 35.6) 3.2 (1.8 to 5.7) 3.4 (2.2 to 4.6) 3.5 (1.8 to 6.7)
Bone sarcoma 23/1.1 21.1 (13.4 to 31.6) 3.3 (1.8 to 6.4) 4.2 (2.4 to 6.0) 3.7 (1.8 to 7.5)
STS 26/1.5 17.1 (11.2 to 25.1) 2.6 (1.4 to 4.8) 3.0 (1.8 to 4.2) 2.9 (1.5 to 5.7)
Other 34/3.8 9.0 (6.2 to 12.5) 1.6 (0.9 to 2.9) 1.7 (1.0 to 2.3) 1.7 (0.9 to 3.3)
Not classifiable‡ 1/0.3 3.7 (0.1 to 20.8) — 0.6 (–1.0 to 2.3) —
Pheterogeneity <.001 <.001 <.001 <.001
Decade of diagnosis
<1970 114/6.9 16.6 (13.7 to 19.9) 1.2 (0.9 to 1.6) 3.7 (3.0 to 4.5) 1.1 (0.8 to 1.5)
1970–1979 84/5.4 15.4 (12.3 to 19.1) Ref 2.5 (1.9 to 3.1) Ref
1980–1989 67/4.7 14.1 (11.0 to 18.0) 0.9 (0.7 to 1.3) 1.8 (1.4 to 2.3) 1.0 (0.7 to 1.4)
1990þ 36/2.1 17.2 (12.1 to 23.9) 1.3 (0.8 to 2.0) 1.8 (1.2 to 2.4) 1.4 (0.8 to 2.2)
Ptrend .63 .69 <.001 .84
Pheterogeneity .70 .41 <.001 .61
Attained age, y
0–19 69/3.2 21.2 (16.5 to 26.9) Ref 1.6 (1.2 to 2.0) Ref
20–29 95/5.6 16.9 (13.6 to 20.6) 0.8 (0.6 to 1.2) 2.3 (1.8 to 2.8) 1.6 (1.1 to 2.2)
30–39 83/5.3 15.8 (12.6 to 19.6) 0.7 (0.5 to 1.1) 3.6 (2.8 to 4.5) 2.5 (1.7 to 3.6)
40þ 54/5.0 10.8 (8.1 to 14.0) 0.5 (0.3 to 0.8) 4.3 (3.0 to 5.5) 2.9 (1.8 to 4.5)
Ptrend <.001 .002 <.001 <.001
Years from diagnosis
5–14 108/5.7 18.8 (15.4 to 22.7) Ref 1.8 (1.4 to 2.2) Ref
15–24 82/5.8 14.2 (11.3 to 17.6) 0.7 (0.5 to 0.9) 2.3 (1.7 to 2.8) 1.2 (0.9 to 1.6)
25–34 58/4.5 13.0 (9.8 to 16.7) 0.5 (0.4 to 0.7) 3.4 (2.4 to 4.3) 1.6 (1.1 to 2.3)
35–44 41/2.3 17.5 (12.6 to 23.8) 0.6 (0.4 to 0.9) 7.1 (4.8 to 9.4) 3.1 (2.0 to 4.8)
45þ 12/0.8 15.0 (7.8 to 26.2) 0.5 (0.2 to 0.9) 9.1 (3.6 to 14.6) 3.7 (1.9 to 7.2)
Ptrend .29 .001 <.001 <.001
*Test for heterogeneity and trend were calculated using two-sided likelihood ratio tests within a univariate Poisson model. AER ¼ absolute excess risk per 10 000 per-
son-years; CI ¼ confidence interval; E ¼ expected number of STS; HB ¼ hospital-based; O ¼ observed number of STS; P ¼ population-based; Ref ¼ reference category;
RER ¼ relative excess risk. RR ¼ relative risk; SIR ¼ standardized incidence ratio.
†Model containing years from diagnosis was adjusted for sex, country, age at diagnosis, childhood cancer diagnosis, and decade of childhood cancer diagnosis. Model con-
taining attained age was adjusted for sex, country, age at diagnosis, childhood cancer diagnosis, and decade of childhood cancer diagnosis. Not-classifiable tumors were ex-
cluded from multivariable analysis. Tests for heterogeneity and trend were calculated using two-sided likelihood ratio tests within a multivariable Poisson model.
‡Childhood cancer survivors diagnosed in Slovenia before 1983 not included in the multivariable model.
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at a young age, with almost a 100-fold risk of developing a leio-
myosarcoma among individuals diagnosed before age five years
(SIR ¼ 98.3, 95% CI¼ 74.4 to 127.4); and the relative risk declined
statistically significantly with older age at diagnosis (RR¼ 0.3,
95% CI¼ 0.1 to 0.8 among survivors age 10 to 19 years vs 0–4
years, Ptrend ¼ .01). Sixty-four point nine percent of survivors di-
agnosed before age five years who developed a leiomyosarcoma
had a known genetic predisposition (35 RB1 mutation, one neu-
rofibromatosis, one Li-Fraumeni syndrome). The relationship
with age at diagnosis remained after excluding survivors of
both retinoblastoma and Wilms tumor from the analysis (Ptrend
¼ .02). No statistically significant relationship between decade
of diagnosis and excess risk of leiomyosarcoma was observed in
either multiplicative or absolute terms. The relative risk did not
vary statistically significantly with attained age or years from
diagnosis (Ptrend ¼ .77 and Ptrend ¼ .52). The relative excess risk
increased substantially with attained age (attained age 40þ vs
0–29 years: RER ¼ 12.5, 95% CI¼ 6.3 to 25.0, Ptrend < .001) and
years from diagnosis (45þ vs five to 24 years from diagnosis:
RER ¼ 28.2, 95% CI¼ 11.0 to 72.1, Ptrend < .001). Beyond 45 years
from diagnosis, the absolute excess risk was 8.7 (95% CI¼ 3.5 to
14.0). The cumulative incidence of developing a leiomyosar-
coma was 0.6% (95% CI¼ 0.4 to 0.8) at 45 years from diagnosis,
whereas 0.02% was expected (Figure 1B).
Risk of Fibromatous Neoplasms
Survivors had a 12.3-fold (95% CI¼ 9.3 to 16.0) increased risk of
developing a fibromatous SPN compared with that expected,
corresponding to an absolute excess risk of 0.4 (95% CI¼ 0.3 to
0.6) (Table 4). Survivors were most at risk of fibrosarcoma (SIR ¼
25.1, 95% CI¼ 16.5 to 36.5) and malignant fibrous histiocytoma
(SIR ¼ 28.3, 95% CI¼ 18.3 to 41.7) (Table 1). Bone sarcoma, reti-
noblastoma, and Hodgkin lymphoma survivors had the high-
est risk of developing a fibromatous SPN, with standardized
incidence ratios of 34.5 (95% CI¼ 15.8 to 65.5), 31.0 (95%
CI¼ 11.4 to 67.5), and 24.2 (95% CI¼ 11.6 to 44.4), respectively
(Table 4); 83.3%, 62.5%, and 50.0% of fibromatous SPNs after
retinoblastoma, Hodgkin lymphoma, and bone sarcoma, re-
spectively, occurred in irradiated tissue (Supplementary Table
4, available online). No statistically significant relationship be-
tween age at diagnosis or decade of diagnosis and excess risk
of fibromatous SPNs was observed in either multiplicative or
absolute terms. Relative risks decreased statistically signifi-
cantly with attained age (30þ vs 0–19 years: RR¼ 0.1, 95%
CI¼ 0.1 to 0.3, Ptrend < .001) and years from diagnosis (25þ vs
five to 14 years from diagnosis: RR¼ 0.2, 95% CI¼ 0.1 to 0.4,
Ptrend < .001), whereas the relative excess risks did not vary
statistically significantly with attained age or years from
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Figure 1. Cumulative incidence of all subsequent primary soft-tissue sarcomas (A), leiomyosarcomas (B), malignant peripheral nerve sheath tumors (C), and fibroma-
tous neoplasms (D) in five-year survivors of childhood cancer, by years from diagnosis. Cumulative incidence was calculated treating death as a competing risk using
the stcompet command in Stata. CNS ¼ central nervous system; HL ¼ Hodgkin lymphoma; MPNST ¼ malignant peripheral nerve sheath tumor; Rb ¼ retinoblastoma;
STS ¼ soft tissue sarcoma.
A
R
T
IC
LE
C. J. Bright et al. | 5 of 12
Downloaded from https://academic.oup.com/jnci/advance-article-abstract/doi/10.1093/jnci/djx235/4643198
by University of Birmingham user
on 29 November 2017
Table 3. Risk of subsequent primary leiomyosarcoma among 69 460 five-year survivors of childhood cancer, by potential explanatory factors
Factor Level O/E SIR (95% CI)* RR (95% CI)† AER (95% CI)* RER (95% CI)†
Overall sex
All combined 80/2.7 29.9 (23.7 to 37.2) 0.7 (0.5 to 0.8)
Male 32/0.9 36.6 (25.0 to 51.7) Ref 0.5 (0.3 to 0.7) Ref
Female 48/1.8 26.6 (19.6 to 35.3) 0.9 (0.6 to 1.5) 0.9 (0.6 to 1.1) 1.7 (1.1 to 2.7)
Pheterogeneity .16 .76 .02 .03
Country
France 17/0.2 84.0 (48.9 to 134.5) Ref 2.0 (1.0 to 3.0) Ref
Hungary 1/0.0 21.7 (0.5 to 120.7) 0.3 (0.0 to 2.4) 0.2 (–0.2 to 0.6) 0.3 (0.0 to 2.2)
Italy‡ 1/0.1 8.0 (0.2 to 44.4) 0.1 (0.0 to 1.1) 0.1 (–0.1 to 0.3) 0.1 (0.0 to 1.3)
Netherlands 4/0.1 27.5 (7.5 to 70.3) 0.5 (0.2 to 1.5) 0.4 (–0.0 to 0.8) 0.5 (0.1 to 1.5)
Nordic countries§ 13/1.3 10.3 (5.5 to 17.7) 0.2 (0.1 to 0.5) 0.3 (0.1 to 0.5) 0.2 (0.1 to 0.5)
Slovenia 0/0.1 — — — —
Switzerland 0/0.1 — — — —
UK 44/0.8 56.0 (40.7 to 75.1) 0.5 (0.3 to 1.0) 1.2 (0.8 to 1.5) 0.5 (0.3 to 1.0)
Pheterogeneity <.001 .002 <.001 .002
Age at diagnosis, y
0–4 57/0.6 98.3 (74.4 to 127.4) Ref 1.2 (0.9 to 1.5) Ref
5–9 10/0.5 20.7 (9.9 to 38.1) 0.6 (0.3 to 1.3) 0.4 (0.1 to 0.6) 0.6 (0.3 to 1.5)
10–19 13/1.6 8.0 (4.3 to 13.8) 0.3 (0.1 to 0.8) 0.3 (0.1 to 0.5) 0.4 (0.1 to 1.0)
Ptrend <.001 .01 <.001 .04
Type of childhood cancer
Leukemia 2/0.2 8.2 (1.0 to 29.5) Ref 0.1 (–0.0 to 0.2) Ref
Hodgkin lymphoma 4/0.2 17.2 (4.7 to 44.0) 4.0 (0.7 to 23.3) 0.4 (–0.0 to 0.9) 4.1 (0.6 to 26.2)
Non-Hodgkin lymphoma 1/0.1 8.2 (0.2 to 45.7) 1.4 (0.1 to 16.2) 0.2 (–0.2 to 0.5) 1.3 (0.1 to 20.6)
Central nervous system 1/0.6 1.7 (0.0 to 9.4) 0.3 (0.0 to 3.7) 0.0 (–0.1 to 0.1) 0.2 (0.0 to 11.7)
Neuroblastoma 2/0.1 28.8 (3.5 to 103.9) 2.0 (0.3 to 15.0) 0.3 (–0.2 to 0.9) 1.8 (0.2 to 14.7)
Retinoblastoma 40/0.1 342.9 (245.0 to 466.9) 30.2 (6.8 to 134.9) 6.6 (4.6 to 8.7) 31.2 (6.6 to 146.9)
Wilms tumor 11/0.1 74.2 (37.1 to 132.8) 5.3 (1.1 to 25.4) 1.1 (0.5 to 1.8) 5.3 (1.0 to 26.7)
Bone sarcoma 5/0.2 28.9 (9.4 to 67.4) 6.6 (1.2 to 36.8) 0.9 (0.1 to 1.8) 6.8 (1.1 to 40.9)
STS 6/0.2 26.4 (9.7 to 57.4) 4.3 (0.8 to 22.4) 0.7 (0.1 to 1.3) 4.4 (0.8 to 24.1)
Other 8/0.7 11.3 (4.9 to 22.4) 3.2 (0.6 to 16.3) 0.4 (0.1 to 0.7) 3.3 (0.6 to 17.9)
Not classifiablek 0/0.0 — — — —
Pheterogeneity <.001 <.001 <.001 <.001
Decade of diagnosis
<1970 48/1.4 33.3 (24.6 to 44.2) 1.0 (0.5 to 2.0) 1.6 (1.1 to 2.1) 1.1 (0.6 to 2.1)
1970–1979 17/0.7 25.0 (14.6 to 40.0) Ref 0.5 (0.3 to 0.8) Ref
1980 15/0.6 26.8 (15.0 to 44.3) 1.8 (0.9 to 3.8) 0.3 (0.1 to 0.4) 1.5 (0.7 to 3.3)
Ptrend .35 .23 <.001 .50
Pheterogeneity .54 .30 <.001 .59
Attained age, y
0–29 22/0.6 35.4 (22.2 to 53.7) Ref 0.3 (0.2 to 0.4) Ref
30–39 26/0.7 37.0 (24.2 to 54.3) 1.1 (0.6 to 2.1) 1.2 (0.7 to 1.6) 5.4 (2.9 to 10.1)
40þ 32/1.4 23.6 (16.1 to 33.3) 0.9 (0.4 to 1.9) 2.7 (1.7 to 3.7) 12.5 (6.3 to 25.0)
Ptrend .13 .77 <.001 <.001
Years from diagnosis
5–24 18/1.0 17.5 (10.4 to 27.6) Ref 0.2 (0.1 to 0.3) Ref
25–34 28/0.8 33.7 (22.4 to 48.6) 1.9 (0.9 to 3.7) 1.7 (1.1 to 2.4) 8.0 (4.0 to 16.1)
35–44 23/0.6 38.3 (24.3 to 57.5) 1.7 (0.7 to 3.8) 4.1 (2.4 to 5.8) 17.0 (7.5 to 38.6)
45þ 11/0.2 50.7 (25.3 to 90.7) 1.3 (0.5 to 3.3) 8.7 (3.5 to 14.0) 28.2 (11.0 to 72.1)
Ptrend .001 .52 <.001 <.001
*Tests for heterogeneity and trend were calculated using two-sided likelihood ratio tests within a univariate Poisson model. — ¼ results not reliable because of small
(or zero) number of STS events; AER ¼ absolute excess risk per 10 000 person-years; CI ¼ confidence interval; E ¼ expected number of STS; HB ¼ hospital-based; O ¼ ob-
served number of STS; PB ¼ population-based; Ref ¼ reference category; RER ¼ relative excess risk. RR ¼ relative risk; SIR ¼ standardized incidence ratio.
†Model containing years from diagnosis was adjusted for sex, country, age at diagnosis, childhood cancer diagnosis, and decade of childhood cancer diagnosis. Model
containing attained age was adjusted for sex, country, age at diagnosis, childhood cancer diagnosis, and decade of childhood cancer diagnosis. Not-classifiable tumors
were excluded from multivariable analysis. Tests for heterogeneity and trend were calculated using two-sided likelihood ratio tests within a multivariable Poisson
model.
‡Because of small numbers, all Italian cohorts were grouped.
§Because of small numbers, all Nordic cohorts were grouped.
kChildhood cancer survivors diagnosed in Slovenia before 1983 not included in the multivariable model.
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Table 4. Risk of subsequent primary fibromatous neoplasms among 69 460 five-year survivors of childhood cancer, by potential explanatory
factors
Factor Level O/E SIR (95% CI)* RR (95% CI)† AER (95% CI)* RER (95% CI)†
Overall sex
All combined 55/4.5 12.3 (9.3 to 16.0) 0.4 (0.3 to 0.6)
Male 36/2.3 15.7 (11.0 to 21.8) Ref 0.6 (0.4 to 0.8) Ref
Female 19/2.2 8.7 (5.2 to 13.6) 0.6 (0.3 to 1.0) 0.3 (0.2 to 0.5) 0.6 (0.3 to 1.2)
Pheterogeneity .03 .06 .08 .14
Country
France 12/0.3 43.0 (22.2 to 75.2) Ref 1.4 (0.6 to 2.2) Ref
Hungary 2/0.1 16.7 (2.0 to 60.5) 0.3 (0.1 to 1.4) 0.4 (–0.2 to 0.9) 0.3 (0.1 to 1.5)
Italy‡ 3/0.3 11.2 (2.3 to 32.9) 0.2 (0.1 to 0.8) 0.3 (–0.1 to 0.7) 0.2 (0.0 to 0.9)
Netherlands 5/0.3 16.9 (5.5 to 39.4) 0.4 (0.1 to 1.1) 0.5 (0.0 to 0.9) 0.4 (0.1 to 1.2)
Nordic countries§ 19/2.2 8.6 (5.2 to 13.5) 0.2 (0.1 to 0.4) 0.5 (0.2 to 0.7) 0.3 (0.1 to 0.7)
Slovenia 1/0.1 11.5 (0.3 to 64.0) 0.5 (0.1 to 4.3) 0.4 (–0.4 to 1.2) 0.4 (0.0 to 6.8)
Switzerland 1/0.1 8.5 (0.2 to 47.3) 0.2 (0.0 to 1.3) 0.2 (–0.2 to 0.6) 0.1 (0.0 to 1.7)
UK 12/1.1 10.8 (5.6 to 18.9) 0.2 (0.1 to 0.5) 0.3 (0.1 to 0.5) 0.2 (0.1 to 0.5)
Pheterogeneity .001 .02 .047 .07
Age at diagnosis, y
0–4 16/1.2 12.9 (7.3 to 20.9) Ref 0.3 (0.1 to 0.5) Ref
5–9 13/0.9 14.6 (7.8 to 25.0) 1.6 (0.7 to 3.8) 0.5 (0.2 to 0.8) 2.0 (0.8 to 5.1)
10–14 15/1.2 12.6 (7.0 to 20.7) 1.8 (0.7 to 4.5) 0.5 (0.2 to 0.9) 2.3 (0.8 to 6.6)
15–19 11/1.1 9.6 (4.8 to 17.1) 2.4 (0.8 to 7.1) 0.6 (0.2 to 1.1) 3.1 (0.9 to 11.3)
Ptrend .44 .20 .07 .09
Type of childhood cancer
Leukemia 3/0.6 5.0 (1.0 to 14.5) Ref 0.1 (–0.0 to 0.3) Ref
Hodgkin lymphoma 10/0.4 24.2 (11.6 to 44.4) 5.1 (1.3 to 20.0) 1.1 (0.4 to 1.8) 7.0 (1.1 to 43.3)
Non-Hodgkin lymphoma 1/0.2 4.5 (0.1 to 25.2) 0.9 (0.1 to 8.7) 0.1 (–0.2 to 0.5) 1.2 (0.1 to 17.9)
Central nervous system 8/1.0 8.2 (3.5 to 16.2) 1.9 (0.5 to 7.3) 0.3 (0.1 to 0.6) 2.3 (0.3 to 14.7)
Neuroblastoma 1/0.1 7.1 (0.2 to 39.3) 1.1 (0.1 to 11.1) 0.2 (–0.2 to 0.5) 1.5 (0.1 to 21.7)
Retinoblastoma 6/0.2 31.0 (11.4 to 67.5) 8.0 (1.8 to 35.3) 1.0 (0.2 to 1.8) 11.5 (1.6 to 83.9)
Wilms tumor 4/0.3 14.2 (3.9 to 36.4) 2.3 (0.5 to 10.9) 0.4 (–0.0 to 0.8) 3.2 (0.4 to 24.2)
Bone sarcoma 9/0.3 34.5 (15.8 to 65.5) 6.9 (1.7 to 27.6) 1.7 (0.6 to 2.8) 9.6 (1.5 to 61.0)
STS 8/0.4 22.6 (9.8 to 44.5) 4.5 (1.2 to 17.9) 0.9 (0.3 to 1.6) 6.4 (1.0 to 41.1)
Other 5/1.0 5.1 (1.7 to 11.9) 1.3 (0.3 to 5.6) 0.2 (–0.0 to 0.5) 1.4 (0.2 to 11.1)
Not classifiablek 0/0.0 — — — —
Pheterogeneity <.001 .001 <.001 .001
Decade of diagnosis
<1970 19/1.7 11.3 (6.8 to 17.7) 1.4 (0.7 to 2.8) 0.6 (0.3 to 0.9) 1.2 (0.6 to 2.5)
1970–1979 16/1.3 12.5 (7.2 to 20.4) Ref 0.5 (0.2 to 0.7) Ref
1980–1989 11/1.1 10.2 (5.1 to 18.3) 0.7 (0.3 to 1.6) 0.3 (0.1 to 0.5) 0.6 (0.3 to 1.5)
1990 9/0.4 20.3 (9.3 to 38.5) 1.3 (0.5 to 3.4) 0.5 (0.1 to 0.8) 1.1 (0.4 to 3.2)
Ptrend .40 .31 .18 .39
Pheterogeneity .44 .34 .33 .42
Attained age, y
0–19 18/0.5 33.5 (19.9 to 53.0) Ref 0.4 (0.2 to 0.6) Ref
20–29 18/1.5 11.8 (7.0 to 18.6) 0.2 (0.1 to 0.5) 0.4 (0.2 to 0.6) 0.6 (0.3 to 1.4)
30þ 19/2.4 7.9 (4.8 to 12.3) 0.1 (0.1 to 0.3) 0.5 (0.2 to 0.8) 0.5 (0.2 to 1.3)
Ptrend <.001 <.001 .65 .17
Years from diagnosis
5–14 26/1.3 19.7 (12.9 to 28.9) Ref 0.4 (0.3 to 0.6) Ref
15–24 19/1.5 12.8 (7.7 to 19.9) 0.5 (0.3 to 1.0) 0.5 (0.3 to 0.8) 1.1 (0.5 to 2.1)
25þ 10/1.7 6.0 (2.9 to 11.0) 0.2 (0.1 to 0.4) 0.4 (0.1 to 0.6) 0.5 (0.2 to 1.4)
Ptrend .001 <.001 .879 .11
*Tests for heterogeneity and trend were calculated using two-sided likelihood ratio tests within a univariate Poisson model. — ¼ results not reliable because of small
(or zero) number of STS events; AER ¼ absolute excess risk per 10 000 person-years; CI ¼ confidence interval; E ¼ expected number of STS; O ¼ observed number of STS;
Ref ¼ reference category; RER ¼ relative excess risk. RR ¼ relative risk; SIR ¼ standardized incidence ratio.
†Model containing years from diagnosis was adjusted for sex, country, age at diagnosis, childhood cancer diagnosis, and decade of childhood cancer diagnosis. Model
containing attained age was adjusted for sex, country, age at diagnosis, childhood cancer diagnosis, and decade of childhood cancer diagnosis. Not-classifiable tumors
were excluded from multivariable analysis. Tests for heterogeneity and trend were calculated using two-sided likelihood ratio tests within a multivariable Poisson
model.
‡Because of small numbers, all Italian cohorts were grouped.
§Because of small numbers, all Nordic cohorts were grouped.
kChildhood cancer survivors diagnosed in Slovenia before 1983 not included in the multivariable model.
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Table 5. Risk of subsequent primary malignant peripheral nerve sheath tumors among 69 460 five-year survivors of childhood cancer, by
potential explanatory factors
Factor Level O/E SIR (95% CI)* RR (95% CI)† AER (95% CI)* RER (95% CI)†
Overall sex
All combined 45/1.1 40.6 (29.6 to 54.3) 0.4 (0.3 to 0.5)
Male 26/0.6 42.1 (27.5 to 61.8) Ref 0.4 (0.3 to 0.6) Ref
Female 19/0.5 38.6 (23.2 to 60.3) 1.0 (0.5 to 1.8) 0.4 (0.2 to 0.5) 0.9 (0.5 to 1.6)
Pheterogeneity .77 1.00 .56 .69
Country
France 6/0.1 93.1 (34.2 to 202.7) Ref 0.7 (0.1 to 1.3) Ref
Hungary 2/0.0 50.2 (6.1 to 181.5) 0.5 (0.1 to 2.7) 0.4 (–0.2 to 0.9) 0.5 (0.1 to 3.0)
Italy‡ 3/0.1 37.6 (7.8 to 109.8) 0.4 (0.1 to 1.9) 0.3 (–0.1 to 0.7) 0.5 (0.1 to 2.1)
Netherlands 3/0.1 35.1 (7.2 to 102.7) 0.4 (0.1 to 1.8) 0.3 (–0.0 to 0.6) 0.5 (0.1 to 2.0)
Nordic Countries§ 14/0.5 29.3 (16.0 to 49.2) 0.3 (0.1 to 0.9) 0.4 (0.2 to 0.6) 0.5 (0.2 to 1.6)
Slovenia 0/0.0 — — — —
Switzerland 3/0.0 78.9 (16.3 to 230.7) 0.9 (0.2 to 4.0) 0.6 (–0.1 to 1.4) 1.0 (0.2 to 4.6)
UK 14/0.3 46.3 (25.3 to 77.7) 0.5 (0.2 to 1.3) 0.4 (0.2 to 0.6) 0.5 (0.2 to 1.5)
Pheterogeneity .33 .53 .80 .83
Age at diagnosis, y
0–4 19/0.4 51.1 (30.7 to 79.8) Ref 0.4 (0.2 to 0.6) Ref
5–9 4/0.2 16.2 (4.4 to 41.4) 0.2 (0.1 to 0.7) 0.1 (–0.0 to 0.3) 0.2 (0.1 to 0.8)
10–14 15/0.3 54.1 (30.3 to 89.2) 0.8 (0.3 to 1.8) 0.6 (0.3 to 0.9) 0.8 (0.3 to 1.9)
15–19 7/0.2 33.0 (13.3 to 67.9) 0.7 (0.2 to 2.3) 0.4 (0.1 to 0.8) 0.7 (0.2 to 2.3)
Ptrend .66 .72 .41 .85
Childhood cancer
Leukemia 3/0.2 15.4 (3.2 to 45.0) Ref 0.1 (–0.0 to 0.3) Ref
Hodgkin lymphoma 8/0.1 81.3 (35.1 to 160.1) 6.1 (1.5 to 25.1) 0.9 (0.3 to 1.5) 6.6 (1.4 to 29.9)
Non-Hodgkin lymphoma 2/0.1 35.7 (4.3 to 128.8) 2.7 (0.4 to 16.6) 0.4 (–0.2 to 0.9) 2.9 (0.4 to 19.7)
Central nervous system 19/0.2 80.5 (48.4 to 125.7) 6.4 (1.8 to 22.6) 0.8 (0.4 to 1.2) 6.9 (1.7 to 27.3)
Neuroblastoma 2/0.0 48.2 (5.8 to 174.3) 2.1 (0.3 to 13.1) 0.4 (–0.1 to 0.9) 2.1 (0.3 to 14.6)
Retinoblastoma 0/0.1 — — — —
Wilms tumor 6/0.1 76.0 (27.9 to 165.4) 3.8 (0.9 to 16.1) 0.6 (0.1 to 1.1) 4.0 (0.9 to 18.9)
Sarcoma§ 3/0.13 21.6 (4.5 to 63.1) 1.5 (0.3 to 7.7)3 0.2 (–0.0 to 0.5) 1.6 (0.3 to 9.0)3
Other 2/0.2 9.8 (1.2 to 35.5) 0.7 (0.1 to 4.6) 0.1 (–0.1 to 0.3) 0.7 (0.1 to 5.3)
Not classifiablek 0/0.0 — — — —
Pheterogeneity .001 <.001 <.001 <.001
Decade of diagnosis
<1970 11/0.3 35.9 (17.9 to 64.3) 0.9 (0.4 to 2.2) 0.4 (0.1 to 0.6) 0.9 (0.4 to 2.1)
1970–1979 12/0.3 39.4 (20.4 to 68.9) Ref 0.4 (0.2 to 0.6) Ref
1980–1989 16/0.3 48.9 (27.9 to 79.4) 1.4 (0.6 to 3.0) 0.5 (0.2 to 0.7) 1.4 (0.7 to 3.2)
1990 6/0.2 35.1 (12.9 to 76.4) 1.0 (0.3 to 3.1) 0.3 (0.1 to 0.6) 1.1 (0.4 to 3.5)
Ptrend .76 .62 .97 .38
Pheterogeneity .84 .82 .86 .67
Attained age, y
0–19 11/0.2 44.6 (22.3 to 79.9) Ref 0.3 (0.1 to 0.4) Ref
20–29 18/0.5 37.6 (22.3 to 59.4) 0.8 (0.4 to 1.8) 0.5 (0.2 to 0.7) 1.7 (0.7 to 3.9)
30þ 16/0.4 41.7 (23.9 to 67.8) 1.0 (0.4 to 2.6) 0.5 (0.2 to 0.7) 1.9 (0.7 to 5.0)
Ptrend .6 .88 .14 .19
Years from diagnosis
5–14 17/0.5 36.8 (21.4 to 58.8) Ref 0.3 (0.1 to 0.4) Ref
15–24 21/0.4 56.7 (35.1 to 86.7) 1.5 (0.7 to 3.0) 0.6 (0.3 to 0.9) 2.2 (1.1 to 4.3)
25þ 7/0.3 25.3 (10.2 to 52.2) 0.6 (0.2 to 1.8) 0.3 (0.1 to 0.5) 1.1 (0.4 to 3.0)
Ptrend .60 .56 .56 .49
*Tests for heterogeneity and trend were calculated using two-sided likelihood ratio tests within a univariate Poisson model. — ¼ results not reliable because of small
(or zero) number of STS events; AER ¼ absolute excess risk per 10 000 person-years; CI ¼ confidence interval; E ¼ expected number of STS; O ¼ observed number of STS;
Ref ¼ reference category; RER ¼ relative excess risk. RR ¼ relative risk; SIR ¼ standardized incidence ratio.
†Model containing years from diagnosis was adjusted for sex, country, age at diagnosis, childhood cancer diagnosis, and decade of childhood cancer diagnosis. Model
containing attained age was adjusted for sex, country, age at diagnosis, childhood cancer diagnosis, and decade of childhood cancer diagnosis. Not-classifiable tumors
were excluded from multivariable analysis. Tests for heterogeneity and trend were calculated using two-sided likelihood ratio tests within a multivariable Poisson
model.
‡Because of small numbers, all Italian cohorts were grouped.
§Because of small numbers, all Nordic cohorts were grouped.
kChildhood cancer survivors diagnosed in Slovenia before 1983 not included in the multivariable model.
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diagnosis (Ptrend ¼ .17, Ptrend ¼ .11, respectively). Absolute ex-
cess risks were generally low at all years from diagnosis (AER
< 1 per 10 000 person-years). The cumulative incidence of de-
veloping a fibromatous neoplasm increased to 0.12% (95%
CI¼ 0.09 to 0.16) at 30 years from diagnosis compared with
0.01% expected (Figure 1C).
Risk of Malignant Peripheral Nerve Sheath Tumors
Malignant peripheral nerve sheath tumors (MPNSTs), such as
malignant schwannoma or neurofibrosarcoma, are rare types of
STS arising from the cells that surround the peripheral nerves.
The highest standardized incidence ratio for any STS subtype
was observed for MPNST SPNs, with a 40.6-fold (95% CI¼ 29.6 to
54.3) increased risk compared with that expected (Table 5); the
corresponding absolute excess risk was 0.4 (95% CI¼ 0.3 to 0.5).
Forty-seven point six percent of all MPNSTs were associated with
neurofibromatosis; 60.0% and 63.6% of MPNSTs occurred within
irradiated tissue among childhood cancer survivors with or with-
out known neurofibromatosis, respectively (Supplementary
Table 5, available online). Standardized incidence ratios were
highest among survivors of central nervous system (CNS) tumors
(SIR ¼ 80.5, 95% CI¼ 48.4 to 125.7), Hodgkin lymphoma (SIR ¼
81.3, 95% CI¼ 35.1 to 160.1), and Wilms tumor (SIR ¼ 76.0, 95%
CI¼ 27.9 to 165.4). Absolute excess risks were generally low at all
years from diagnosis (AER < 1 per 10 000 person-years). No sta-
tistically significant trends in excess risk were observed in
relation to years from diagnosis, attained age, age at diagno-
sis, or decade of diagnosis in multiplicative or absolute
terms. The cumulative incidence of developing an MPNST
reached 0.1% (95% CI¼ 0.07 to 0.14) at 30 years from diagno-
sis, whereas 0.002% was expected (Figure 1D).
Risk of STS Among Retinoblastoma Survivors
As survivors of retinoblastoma experienced the highest risk of
developing an STS (SIR ¼ 72.8, 95% CI¼ 56.1 to 93.0), particularly
leiomyosarcoma (SIR ¼ 342.9, 95% CI¼ 245.0 to 466.9), we inves-
tigated the risks by the potential explanatory factors in more
detail (Table 6 and 7). Seventy-six point nine percent of leio-
myosarcomas observed after retinoblastoma developed outside
of irradiated tissue, and of this particular group, 86.7% represent
Table 6. Risk of all subsequent primary STS among 2578 five-year survivors of retinoblastoma, by potential explanatory factors
Factor Level O/E SIR (95% CI)* RR (95% CI)† AER (95% CI)* RER (95% CI)†
Overall sex
All combined 64/0.9 72.8 (56.1 to 93.0) 10.5 (7.9 to 13.1)
Male 31/0.5 64.1 (43.5 to 90.9) Ref 9.7 (6.2 to 13.2) Ref
Female 33/0.4 83.5 (57.5 to 117.3) 1.3 (0.8 to 2.2) 11.3 (7.4 to 15.2) 1.2 (0.7 to 2.0)
Pheterogeneity .29 .31 .56 .57
Country
France 7/0.1 133.3 (53.6 to 274.7) Ref 18.9 (4.8 to 33.0) Ref
Hungary 2/0.0 137.7 (16.7 to 497.2) 1.4 (0.3 to 6.8) 13.1 (–5.2 to 31.3) 1.3 (0.3 to 6.4)
Italy‡ 0/0.0 — — — —
Netherlands 3/0.0 391.9 (80.8 to 1145.2) 3.4 (0.9 to 13.4) 46.4 (–6.2 to 99.0) 3.5 (0.9 to 13.7)
Nordic Countries§ 11/0.3 42.0 (21.0 to 75.2) 0.3 (0.1 to 0.7) 6.4 (2.5 to 10.3) 0.3 (0.1 to 0.7)
Slovenia 0/0.0 — — — —
Switzerland 0/0.0 — — — —
UK 41/0.5 82.4 (59.1 to 111.8) 0.5 (0.2 to 1.2) 12.1 (8.3 to 15.8) 0.5 (0.2 to 1.1)
Pheterogeneity .003 .002 .009 .003
Decade of diagnosis
<1970 45/0.5 82.2 (59.9 to 110.0) Ref 14.7 (10.4 to 19.1) Ref
1970 19/0.3 57.3 (34.5 to 89.5) 0.8 (0.4 to 1.5) 6.2 (3.4 to 9.1) 0.8 (0.4 to 1.6)
Ptrend .19 .30 .001 .40
Pheterogeneity .19 .30 .001 .40
Attained age, y
0–29 21/0.4 49.2 (30.4 to 75.2) Ref 4.5 (2.6 to 6.5) Ref
30–39 21/0.2 90.3 (55.9 to 138.1) 1.7 (0.9 to 3.3) 21.7 (12.3 to 31.1) 4.7 (2.4 to 9.0)
40þ 22/0.2 100.2 (62.8 to 151.8) 1.8 (0.9 to 3.8) 40.8 (23.6 to 58.0) 8.7 (4.3 to 17.7)
Ptrend .01 .06 <.001 <.001
Years from Diagnosis
5–24 18/0.4 50.1 (29.7 to 79.1) Ref 4.3 (2.3 to 6.3) Ref
25–34 18/0.2 75.2 (44.6 to 118.8) 1.4 (0.7 to 2.7) 15.5 (8.2 to 22.7) 3.5 (1.8 to 6.9)
35–44 17/0.2 93.1 (54.2 to 149.0) 1.6 (0.8 to 3.6) 30.1 (15.6 to 44.5) 6.8 (3.2 to 14.8)
45þ 11/0.1 113.1 (56.5 to 202.5) 1.9 (0.8 to 4.5) 57.7 (23.3 to 92.1) 12.7 (5.3 to 30.0)
Ptrend .02 .12 <.001 <.001
*Tests for heterogeneity and trend were calculated using two-sided likelihood ratio tests within a univariate Poisson model. — ¼ results not reliable because of small
(or zero) number of STS events; AER ¼ absolute excess risk per 10 000 person-years; CI ¼ confidence interval; E ¼ expected number of STS; O ¼ observed number of STS;
Ref ¼ reference category; RER ¼ relative excess risk. RR ¼ relative risk; SIR ¼ standardized incidence ratio.
†Model containing years from diagnosis was adjusted for sex, country, age at diagnosis, childhood cancer diagnosis, and decade of childhood cancer diagnosis. Model con-
taining attained age was adjusted for sex, country, age at diagnosis, childhood cancer diagnosis, and decade of childhood cancer diagnosis. Not-classifiable tumors were ex-
cluded from multivariable analysis. Tests for heterogeneity and trend were calculated using two-sided likelihood ratio tests within a multivariable Poisson model.
‡Because of small numbers, all Italian cohorts were grouped.
§Because of small numbers, all Nordic cohorts were grouped.
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heritable retinoblastoma (Supplementary Table 4, available on-
line). The absolute excess risk for STS among survivors of reti-
noblastoma increased substantially with increasing years from
diagnosis and attained age (Ptrend < .001), reaching 57.7 (95%
CI¼ 23.3 to 92.1) beyond 45 years from diagnosis (Table 6).
Beyond 45 years from diagnosis, leiomyosarcomas accounted
for 91.3% of all excess STS among retinoblastoma survivors,
with an absolute excess risk of 52.7 (95% CI¼ 20.0 to 85.5) (Table
7). The cumulative incidence of developing an STS among reti-
noblastoma survivors was 5.4% (95% CI¼ 3.9 to 7.3) at 45 years
from diagnosis, whereas 0.07% was expected (Figure 1A). The
cumulative incidence of developing a leiomyosarcoma was 3.7%
(95% CI¼ 2.4 to 5.3) at 45 years from diagnosis, whereas 0.01%
was expected (Figure 1B).
Sensitivity Analyses
To verify that the risk estimates reported were not sensitive to
the general population rate applied, we conducted a sensitivity
analysis in which we used only UK rates, or separately only
Finnish rates for all countries. This additional analysis revealed
that excess risk estimates were very similar regardless of the
general population rates applied (Supplementary Tables 6 and
7, available online).
To investigate the observed heterogeneity between contribut-
ing cohorts, we conducted a sensitivity analysis in which we ex-
cluded each cohort in turn. When the French cohort was
excluded, the Pheterogeneity value in relative risks between cohorts
was no longer statistically significant (Pheterogeneity ¼ .08). In addi-
tion, standardized incidence ratios, absolute excess risks, relative
risks, and relative excess risks were remarkably similar to those
presented here; therefore, we did not exclude the French cohort
in our analyses (Supplementary Table 8, available online).
Discussion
This study provides unprecedented insight into the absolute
and excess risks of STS SPN after childhood cancer, particularly
in the long term. The only previous large-scale study addressing
this topic that did not contribute data to PanCareSurFup is the
Table 7. Risk of all subsequent primary leiomyosarcoma among 2578 five-year survivors of retinoblastoma, by potential explanatory factors
Factor Level O/E SIR (95% CI)* RR (95% CI)† AER (95% CI)* RER (95% CI)†
Overall sex
All combined 40/0.1 342.9 (245.0 to 466.9) 6.6 (4.6 to 8.7)
Male 17/0.0 429.4 (250.1 to 687.4) Ref 5.4 (2.8 to 8.0) Ref
Female 23/0.1 298.5 (189.2 to 447.9) 0.8 (0.4 to 1.5) 7.9 (4.7 to 11.2) 1.5 (0.8 to 2.8)
Pheterogeneity .25 .35 .23 .27
Country
France 5/0.0 1027.6 (333.7 to 2398.0) Ref 13.6 (1.7 to 25.5) Ref
Hungary 1/0.0 1233.0 (31.2 to 6869.8) 1.4 (0.2 to 12.9) 6.6 (–6.3 to 19.5) 1.2 (0.1 to 11.1)
Italy‡ 0/0.0 — — — —
Netherlands 0/0.0 — — — —
Nordic Countries§ 5/0.0 143.2 (46.5 to 334.1) 0.1 (0.0 to 0.5) 3.0 (0.3 to 5.6) 0.2 (0.0 to 0.6)
Slovenia 0/0.0 — — — —
Switzerland 0/0.0 — — — —
UK 29/0.1 401.8 (269.1 to 577.1) 0.4 (0.1 to 1.1) 8.6 (5.5 to 11.8) 0.4 (0.2 to 1.2)
Pheterogeneity .04 .07 .04 .08
Decade of diagnosis
<1970 31/0.1 334.8 (227.5 to 475.2) Ref 10.2 (6.6 to 13.8) Ref
1970 9/0.0 374.2 (171.1 to 710.3) 1.1 (0.4 to 3.1) 3.0 (1.0 to 5.0) 1.0 (0.4 to 2.7)
Ptrend .77 .98 <.001 .86
Pheterogeneity .77 .98 <.001 .86
Attained age, y
0–29 7/0.0 267.8 (107.7 to 551.7) Ref 1.5 (0.4 to 2.7) Ref
30–39 13/0.0 401.4 (213.7 to 686.5) 1.6 (0.6 to 4.5) 13.6 (6.2 to 21.0) 8.8 (3.3 to 23.5)
40þ 20/0.1 344.1 (210.2 to 531.4) 1.5 (0.5 to 4.6) 37.3 (20.9 to 53.7) 25.5 (9.1 to 71.2)
Ptrend .60 .37 <.001 <.001
Years from diagnosis
5–24 6/0.0 298.7 (109.6 to 650.2) Ref 1.4 (0.3 to 2.6) Ref
25–34 11/0.0 380.9 (190.1 to 681.5) 1.3 (0.4 to 3.7) 9.5 (3.9 to 15.2) 6.3 (2.3 to 17.5)
35–44 13/0.0 332.1 (176.8 to 567.9) 1.2 (0.4 to 3.9) 23.2 (10.5 to 35.8) 15.9 (5.2 to 48.3)
45þ 10/0.0 350.3 (168.0 to 644.3) 1.2 (0.4 to 4.1) 52.7 (20.0 to 85.5) 34.9 (10.8 to 112.8)
Ptrend .86 .83 <.001 <.001
*Tests for heterogeneity and trend were calculated using two-sided likelihood ratio tests within a univariate Poisson model. — ¼ results not reliable because of small
(or zero) number of STS events; AER ¼ absolute excess risk per 10 000 person-years; CI ¼ confidence interval; E ¼ expected number of STS; O ¼ observed number of STS;
Ref ¼ reference category; RER ¼ relative excess risk. RR ¼ relative risk; SIR ¼ standardized incidence ratio.
†Model containing years from diagnosis was adjusted for sex, country, age at diagnosis, childhood cancer diagnosis, and decade of childhood cancer diagnosis. Model
containing attained age was adjusted for sex, country, age at diagnosis, childhood cancer diagnosis, and decade of childhood cancer diagnosis. Not-classifiable tumors
were excluded from multivariable analysis. Tests for heterogeneity and trend were calculated using two-sided likelihood ratio tests within a multivariable Poisson
model.
‡Because of small numbers, all Italian cohorts were grouped.
§Because of small numbers, all Nordic cohorts were grouped.
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North American Childhood Cancer Survivor Study (CCSS) (9),
which included 108 subsequent primary sarcomas (both bone
and soft tissue combined) compared with our 301 STS alone.
More importantly, the CCSS study reported six observed subse-
quent primary sarcomas beyond 30 years from diagnosis (9),
while in PanCareSurFup this was 80.
We provide, for the first time, separate risk estimates for spe-
cific histological types of STS. Childhood cancer survivors are at
risk of developing an STS SPN, particularly leiomyosarcoma,
MPNSTs, and fibromatous SPNs. Among childhood cancer survi-
vors, as years from diagnosis and attained age increased, the stan-
dardized incidence ratio for fibromatous SPNs decreased; in
contrast, the standardized incidence ratio for leiomyosarcoma
and MPNST remained consistently high across all years from diag-
nosis and at all attained ages. With regards to the absolute excess
risks, the number of excess fibromatous SPNs and MPNSTs
remained low across all years from diagnosis and at all attained
ages. In contrast, the number of excess leiomyosarcomas in-
creased with increasing years from diagnosis and attained age, es-
pecially among retinoblastoma survivors. This risk of STS SPNs
reported is broadly consistent with the largest studies published
so far (4–6,9–11). To our knowledge, our study is the first to identify
a substantially increased risk of leiomyosarcoma in Wilms tumor
survivors. This increase in risk is likely related to radiotherapy be-
cause the majority of leiomyosarcomas observed after Wilms tu-
mor developed within tissue directly irradiated. The high risk of
leiomyosarcoma among retinoblastoma survivors is consistent
with previous literature (14,16,28) and is most likely caused by a
genetic predisposition (heritable retinoblastoma/RB1 mutation)
(15,28)—the majority of such leiomyosarcomas developed outside
of tissue directly irradiated to treat the retinoblastoma, and most
of these retinoblastomas were known to be heritable. The strong
relationship observed between age at childhood cancer and the
excess risk of leiomyosarcoma is likely due to a genetic
predisposition.
The excess risk of fibromatous SPNs after Hodgkin lym-
phoma and bone sarcoma can be attributed to radiotherapy, to
at least some extent, as 63% and 50% of the fibromatous SPNs
observed after Hodgkin lymphoma and bone sarcoma devel-
oped within tissue directly irradiated. Kleinerman et al. identi-
fied an increased risk of both fibrosarcoma (398-fold) and
malignant fibrous histiocytoma (100-fold) among survivors of
heritable retinoblastoma (15). The current study included few
retinoblastoma survivors who developed a fibromatous neo-
plasm; therefore, detailed comparison is not possible.
Neurofibromatoses are genetic conditions associated with
the development of cancer, particularly MPNSTs and CNS
tumors (gliomas) (29). In our cohort, the proportion of MPNSTs
that developed in tissue directly irradiated to treat the child-
hood cancer was similar irrespective of whether neurofibroma-
tosis was known to be present of not. This suggests that
radiotherapy is an independent risk factor for MPNST, which is
consistent with previous literature (30,31).
Over the last few decades, cumulative therapeutic expo-
sures have decreased for cancers with a favorable prognosis;
however, within PanCareSurFup, the excess risk of developing
any type of STS did not vary statistically significantly across
decades of diagnosis. Consequently, there is no evidence so
far that interventions to reduce the toxicity of cancer treat-
ments are having a measurable impact on the long-term risk
of STS SPNs.
A potential limitation of our study is the observed statisti-
cally significant heterogeneity between the contributing cohorts
(Table 2). A large proportion of survivors in the French cohort
attended the Gustave Roussy and the Institut Curie, which are
referral centers for relapsed and recurrent disease. Therefore, it
was anticipated that cumulative doses of radiotherapy adminis-
tered to patients at these centers would be higher than in a
population-based setting.
A limitation is the absence of detailed information on cumu-
lative radiotherapy and chemotherapy exposure during treat-
ment for the childhood cancer. However, a nested case–control
study is in progress that will relate the risk of STS SPN to cumu-
lative doses of radiation from radiotherapy and cumulative
doses of individual cytotoxic drugs.
We provide here, for the first time, risk estimates of specific
STS subtypes following childhood cancer and give evidence that
survivors are particularly at risk for MPNSTs, leiomyosarcomas,
and fibromatous neoplasms. While the multiplicative excess
risks relative to the general population were substantial, the ab-
solute risk of developing any STS subtype was low, except for
leiomyosarcoma after retinoblastoma. Despite attempts to re-
duce therapeutic exposures for specific cancers over the last
few decades, the excess risk of STS did not vary across different
decades of diagnosis. This study provides unprecedented in-
sight into the absolute and excess risks of STS SPN after child-
hood cancer, particularly in the long term, which is likely to be
informative to both childhood cancer survivors and health care
providers.
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